We confirmed that SARS-CoV-2 infection triggers NLRP3 inflammasome engagement in monocytes, because glyburide, a drug for treatment of type 2 diabetes which modulates ATP-dependent K+ channel22, could prevent virus-induced cell lysis. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.